

Breo[®] Ellipta[®] (fluticasone furoate/vilanterol trifenate) – First-time authorized brand alternative

- On May 24, 2022, Prasco launched an authorized brand alternative of GSK's [Breo Ellipta \(fluticasone furoate/vilanterol trifenate\)](#) inhalation aerosol.
- Breo Ellipta is approved for the once-daily treatment of asthma in patients aged 18 years and older, and the 100 mcg/25 mcg strength is approved for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- Inhaled fluticasone furoate is also available as brand inhalation powder ([Arnuity[®] Ellipta](#)) and approved for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older.
- Inhaled fluticasone furoate is also available in combination with umeclidinium bromide and vilanterol trifenate as a brand inhalation powder ([Trelegy[®] Ellipta](#)) and approved for the maintenance treatment of patients with COPD and for the maintenance treatment of asthma in patients aged 18 years and older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.